About Kalvista
KalVista is a biopharmaceutical company discovering, developing and commercializing oral protease inhibitor drugs based on deep expertise in the kallikrein-kinin system. Our commitment to rigorous science is driven by our determination to better address treatment needs for patients, beginning with hereditary angioedema (HAE), a rare genetic disease with unpredictable attacks of tissue swelling that can be life threatening.
Resources
Learn about hereditary angioedema, the treatment landscape, and unmet needs that exist for people living with this rare disorder.
An overview of our patient support program for U.S. residents.
Our company logo.
An overview of KalVista, our science, clinical trials, and purpose.
